系统性硬化症相关间质性肺病的生物标志物:文献综述
本文综述了系统性硬化症相关间质性肺病(SSc-ILD)的生物标志物。SSc-ILD进展谱广,免疫抑制治疗不应给予稳定或非进展性疾病,正确识别高进展风险疾病仍是挑战,生物标志物亟需。已按不同生物学通路鉴定并分类八类生物标志物,本文旨在描述在SSc-ILD诊断和预后中具有临床价值的主要生物标志物。
要点
- SSc-ILD进展谱广,稳定或非进展性疾病不应给予积极免疫抑制治疗。
- 正确识别高进展风险SSc-ILD患者是早期治疗干预的挑战。
- 已按不同生物学通路鉴定并分类八类生物标志物。
核心结论
- SSc-ILD生物标志物亟需,以识别高进展风险患者并指导早期治疗干预。
研究设计与样本
- 本文为文献综述,旨在描述SSc-ILD诊断和预后中具有临床价值的主要生物标志物。
主要发现
- 已鉴定并分类八类生物标志物,依据涉及的不同生物学通路。
临床怎么用
- 临床需识别高进展风险SSc-ILD患者以进行早期治疗干预,避免对稳定或非进展性疾病给予积极免疫抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SSc is a rare disease of unknown origin associated with multiple organ involvement. One of the major complications that drives the mortality of SSc patients is interstitial lung disease. The course of SSc-interstitial lung disease progression has a wide spectrum. Since the treatment is based on aggressive immunosuppression it should not be given to stable or non-progressing disease. The correct identification of disease with high risk of progression remains a challenge for early therapeutic intervention, and biomarkers remain urgently needed. In fact, eight categories of biomarkers have been identified and classified according to the different biological pathways involved. The purpose of this article is to describe the main biomarkers thought to be of interest with clinical value in the diagnosis and prognosis of SSc-interstitial lung disease.
引用
- Bonhomme O, André B, Gester F, et al. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology (Oxford). 2019. PMID: 31292645. doi:10.1093/rheumatology/kez230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。